CDH1致病性变异携带者胃印戒细胞癌的相关因素:GASTRIC联盟报告
该回顾性观察研究纳入12个学术中心1998至2025年的390例CDH1携带者,分析内镜和病理特征与局限性或进展期胃印戒细胞癌的关系。基线内镜活检发现印戒细胞癌对进展期病变最敏感(0.81),但阳性预测值低(0.21);肿块和皱襞增厚特异性高(0.99和0.96)。无内镜异常者未见进展期癌,提示内镜监测或可替代手术。
要点
- 基线内镜活检发现印戒细胞癌是进展期病变最敏感特征(敏感性0.81),但阳性预测值仅0.21。
- 肿块和皱襞增厚对进展期癌特异性高(0.99和0.96),但敏感性较低。
- 无内镜异常表现的携带者未见进展期癌,内镜监测或可替代预防性胃切除术。
核心结论
- CDH1携带者中,内镜无异常发现令人安心,而内镜和病理异常的意义尚不明确。
- 进展期癌仅见于少数携带者,且几乎所有病例均伴内镜异常。
- 无令人担忧黏膜表现的携带者,内镜监测或可替代手术。
研究设计与样本
- 回顾性观察研究,纳入12个学术中心1998至2025年的390例CDH1携带者(来自235个家族)。
主要发现
- 390例携带者中,196例(52.4%)接受胃切除术,其中11例(5.6%)为进展期癌,10例(90.9%)伴内镜异常。
- 内镜活检发现印戒细胞癌对进展期病变敏感性0.81、特异性0.74、阳性预测值0.21。
- 肿块和皱襞增厚特异性分别为0.99和0.96,但敏感性较低;阴性预测值高(0.94-1.0),阳性预测值中等(0.13-0.66)。
- 多变量分析显示,基线内镜发现肿块和印戒细胞癌灶是进展期病变的独立预测因素。
关键数值与推荐
- 内镜活检发现印戒细胞癌:敏感性0.81,特异性0.74,阳性预测值0.21。
- 肿块:特异性0.99;皱襞增厚:特异性0.96。
- 阴性预测值范围0.94-1.0,阳性预测值范围0.13-0.66。
临床怎么用
- 对CDH1携带者进行内镜监测时,无异常黏膜表现者可考虑暂不手术。
- 发现肿块或皱襞增厚等高度特异性表现时,应警惕进展期癌。
- 活检发现印戒细胞癌需结合其他内镜特征综合评估,因其阳性预测值较低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Gastric cancer surveillance in CDH1 pathogenic variant carriers is challenging, as predictors of localized (stage T1a) and advanced (stage >T1a) signet ring cell carcinoma (SRCC) are not well-defined. We established the Group of Investigators Striving Toward Research in CDH1 (GASTRIC) consortium to identify clinicopathologic factors associated with localized and advanced SRCC. METHODS: A retrospective observational study (1998-2025) of CDH1 carriers across 12 academic centers was performed. Clinical, endoscopic, and pathologic data were compared between carriers with and without SRCC on endoscopy, and between those with advanced vs localized or no cancer on gastrectomy specimens. RESULTS: Overall, 390 CDH1 carriers from 235 families were included. The presence of biopsy-detected SRCCs on endoscopy was significantly associated with thickened folds, nodularity, masses, and intestinal metaplasia, whereas gastritis was negatively associated. Of 196 carriers (52.4%) undergoing gastrectomy, 11 (5.6%) had advanced cancers, 10 (90.9%) of which showed endoscopic abnormalities. Identification of biopsy-detected SRCC on baseline endoscopy was the most sensitive feature for advanced disease (0.81) but had moderate specificity (0.74) and low positive predictive value (0.21), whereas masses and thickened folds were highly specific (0.99 and 0.96, respectively) but less sensitive. The negative predictive values were high (0.94-1.0), whereas the positive predictive values were modest (0.13-0.66). On multivariable analysis, masses and SRCC foci on baseline endoscopy were independent predictors of advanced disease. CONCLUSIONS: Among CDH1 carriers, the absence of endoscopic findings was reassuring, whereas the significance of detected endoscopic and pathologic abnormalities was less certain. Advanced cancer occurred in a small number of carriers, with endoscopic abnormalities in nearly all cases. Endoscopic surveillance might be an alternative to surgery in carriers without worrisome mucosal findings.
引用
- Gilad O, Drogan CM, Keel E, et al. Factors Associated With Gastric Signet Ring Cell Carcinoma in CDH1 Pathogenic Variant Carriers: Report From the Group of Investigators Striving Toward Research in CDH1 Consortium. Clin Gastroenterol Hepatol. 2026. PMID: 42604658. doi:10.1016/j.cgh.2026.07.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。